BioSpace News Archive

Fate Therapeutics, Inc. presented preclinical data of several novel strategies designed to enable administration of off-the-shelf cell-based cancer immunotherapies without conditioning chemotherapy at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI) today announced data from the ESMO Asia Congress 2022 and the American Society of Hematology (ASH) Annual Meeting about the use of lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small cell lung cancer (NSCLC) patients.

Sharps Technology, Inc. (the “Company”, “Sharps”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals.

Erasca, Inc. today announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for ERAS-3490.

Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment.

KaliVir Immunotherapeutics, Inc. today announced that it has appointed the following experts to its clinical and scientific advisory boards.

Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of-its-kind, purpose built, focal pulsed field ablation therapy integrated seamlessly with 3D mapping & navigation.

Lantern Pharma Inc. today announced that it has expanded development of its drug candidate LP-184 to include Triple Negative Breast Cancer (TNBC), one of the most aggressive and malignant forms of breast cancer.

vTv Therapeutics Inc. today announced the appointment of Steven Tuch as Chief Financial Officer, effective immediately.

Tellus Therapeutics announced today the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund.